Coastar Therapeutics, Inc.
Coastar Therapeutics is a San Diego-based biotech company dedicated to developing biological payload delivery technologies for cancer and gene therapies. Their proprietary ENHEnSTM technology coats cell membranes on biological payloads to evade immune recognition and deliver to disease sites, aiming to improve efficacy, reduce toxicity, and lower treatment costs. The company is actively involved in advancing gene and cell therapy delivery systems, collaborating with global partners, and participating in industry conferences to showcase their innovative solutions.
Industries
Nr. of Employees
small (1-50)
Coastar Therapeutics, Inc.
San Diego, California, United States, North America
Products
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
Services
Platform collaboration for delivery of biologics and gene therapies
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Analytical method and bioassay development
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Process development and technical transfer for scalable production
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
GMP manufacturing support and audit readiness
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Preclinical development support toward IND-enabling studies
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Platform collaboration for delivery of biologics and gene therapies
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Analytical method and bioassay development
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Process development and technical transfer for scalable production
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
GMP manufacturing support and audit readiness
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Preclinical development support toward IND-enabling studies
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Expertise Areas
- Gene delivery and nanocarrier platforms
- Oncolytic virotherapy delivery
- Viral vector (AAV, lentivirus) production and characterization
- In vivo and in vitro genome-editing delivery
Key Technologies
- Erythrocyte-derived membrane nanocarriers (cell membrane coating)
- Oncolytic virus delivery
- AAV vector delivery
- Lentiviral transduction and production